4887 results about "Carbamate" patented technology

Fast curing surgical adhesives and sealants contain an NCO-terminated hydrophilic urethane prepolymer derived from an aromatic diisocyanate and a polyol. Substantially all the aromatic diisocyanate used to prepare the NCO-terminated hydrophilic urethane prepolymer is in the para form. Optionally, the aromatic diisocyanate is substituted with at least one electron withdrawing group, such as, for example, a fluorine group.

A polyurethane based prepolymer is provided and useful in biomedical devices which provides high oxygen permeability and superior physical properties. A hydrogel is produced from a comonomer mixture containing a polysiloxane-containing urethane prepolymer, tris(trimethylsiloxy)-silylpropyl methacrylate and a hydrophilic comonomer. The hydrogel is especially useful for biomedical materials such as contact lenses and implants.

This invention provides a film comprising a cross-linked polymer having an oxyalkylene group or a cross-linked polymer having an oxyalkylene group through a urethane bond, as a constituent component, a production method of the film, and an electrochemical apparatus using the film as a separator. The film for separator of an electrochemical apparatus can be easily and uniformly processed, can include an electrolytic solution, exhibits good film thickness and ensures excellent safety and reliability. The electrochemical apparatus is free of leakage of the solution.

The present invention is directed to novel organometallic complexes as catalysts for the reaction of compounds with isocyanate and hydroxyl functional groups to form urethane and/or polyurethane and the process employing such catalysts. More particularly, the present invention is directed to novel complexes of zinc(II) with substituted amidines. These novel catalysts are useful for the production of urethanes and polyurethanes which are important in many industrial applications.

Disclosed is a method of down-regulating the expression of a gene in an animal, wherein a pharmacological formulation comprising a chimeric oligonucleotide complementary to the gene is orally administered to an animal. The oligonucleotide administered has at least one phosphorothioate internucleotide linkage and at least one alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, phosphoramidite, phosphate ester, carbamate, carbonate, phosphate triester, acetamidate, or carboxymethyl ester internucleotide linkage.

The invention relates to polymers with antimicrobial properties, consisting of: a) 99-40 wt % non functional vinylically polymerizable monomers and b) 1-60 wt % functional vinylically polymerizable monomers of general formula (I) wherein V=vinyl, (meth)acroyl, allyl or styryl, A=a possibly available linking unit, which can be alkyl, aryl, arylalkyl or hydroxy alkyl, which can also be interrupted by hetero atoms, e.g. by hetero atoms in urethane, carbonate, ester, amide or ether groups, wherein y=0 or is 1, Hsp=a hydrophilic spacer of general formula (i) -(O-CH2-CH2)r- and/or (ii) -(O-CH2-CH(CH3))s with r=0-40, s=0-40 and r+s=2-40, also m=1.2 or 3 and R1=CH3, ethyl or benzyl, R2=an alkyl radical with 8-20 C-atoms, wherein t=1, 2 or 3 and X-=Cl-, Br-, I- or alkyl sulphate.

The present invention relates to novel compounds according to the to the general formulas I, II, III, IV or V: wherein B is nucleoside base according to the structure: R is H, F, Cl, Br, I, C1-C4 alkyl (preferably CH3), -C=N, -C=C-Ra, X is H, C1-C4 alkyl (preferably, CH3), F, Cl, Br or I; Z is O or CH2, with the proviso that Z is CH2 and not O when the compound is according to general formula II, R<3 >is -C=C-H and R<2 >is H or a phosphate, diphosphate, triphosphate or phosphotriester group; R<1 >is H, an acyl group, a C1-C20 alkyl or an ether group; R<2 >is H, an acyl group, a C1-C20 alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a group; Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety; R<8 >is H, or a C1-C20 alkyl or ether group, preferably a C1-C12 alkyl group; k is 0-12, preferably, 0-2; R<3 >is selected from a C1-C4 alkyl (preferably, CH3), -(CH2)n-C=C-Ra, R<3a >and R<3b >are independently selected from H, F, Cl, Br or I; R<4 >and R<5 >are independently selected from H, F, Cl, Br, I, OH, C1-C4 alkyl (preferably, CH3), -(CH2)n-C=C-Ra, with the proviso that R<4 >and R<5 >are not both H; Ra is H, F, Cl, Br, I, or -C1-C4 alkyl, preferably H or CH3; Y is H, F, Cl, Br, I or -C1-C4 alkyl, preferably H or CH3; and n is 0, 1, 2, 3, 4 or 5, preferably 0, 1 or 2; and their anomers, pharmaceutically acceptable salts, solvates, or polymorphs thereof.

A solid golf ball with a polyurethane cover having satisfactory formability and ball properties. The solid golf ball has a solid core, and a polyurethane cover for covering the solid core, wherein the difference in Shore D hardness between a center portion and a surface portion of the solid core is at least 15; the polyurethane cover has a thickness (t) of not more than 1.0 mm, and is formed from a cured urethane composition having Shore D hardness (D) of from 35 to 60; a product of the thickness(t) and the Shore D Hardness (D) of the cured urethane composition is ranging from 10 to 45(10≦D×t≦45); and the urethane composition contains an isocyanate group-terminated urethane prepolymer having the residual polyisocyanate monomer content of not more than 0.1 mass %, and an aromatic polyamine compound.

A pyrrolobenzodiazepine dimer compound of Formula (I): or pharmaceutically acceptable salt or solvate thereof is useful as a therapeutic agent for the treatment of leukaemias, especially B-cell leukaemias, that exhibit resistance to other chemotherapeutic drugs, wherein: the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3; R² and R³ are independently selected from —H, ═O, ═CH₂, —CN, —R, OR, halo, ═CH—R, O—SO₂—R, CO₂R and COR; R⁶, R⁷ and R⁹ are independently selected from II, R, OII, OR, SII, SR, NII₂, NIIR, NRR′, nitro, Me₃Sn and halo; where R and R′ are independently selected from optionally substituted C_1-12 alkyl, C_3-20 heterocyclyl and C_5-20 aryl groups; R¹⁰ is a carbamate-based nitrogen protecting group and R¹⁵ is either O—R¹¹, wherein R is an oxygen protecting group, or OH, or R¹⁰ and R¹⁵ together form a double bond between N10 and C11; R″ is a C_3-12 alkylene group, which chain may be interrupted by one or more heteroatoms and/or aromatic rings, and each X is independently selected from 0, S, or NH; R^2′, R^3′, R^6′, R^7′, R^9′, R^10′ and R^15′ are all independently selected from the same lists as previously defined for R², R³, R⁶, R⁷, R⁹, R¹⁰ and R¹⁵ respectively.

The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C_1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.

Described herein are carbamate compounds. Such compounds are capable of modulating the activity of a checkpoint kinase, and described herein are methods for utilizing such modulation to treat cell proliferative disorders. Also described are pharmaceutical compositions containing such compounds. Also described are the therapeutic or prophylactic use of such compounds and compositions, and methods of treating cancer as well as other diseases associated with unwanted cellular proliferation, by administering effective amounts of such compounds in combination with anti-neoplastic agents.

An ink composition containing at least a polymerizable composition, a pigment, and a polymer represented by General Formula (1):

where R¹ represents an (m+n)-valent organic linking group, R² represents a single bond or divalent organic linking group; A¹ represents a monovalent organic group having a pigment adsorption structure that contains at least one selected from organic pigment structure, heterocyclic structure, acidic group, group having a basic nitrogen atom, urea group, urethane group, group having a coordinating oxygen atom, hydrocarbon group having 4 or more carbon atoms, alkoxysilyl group, epoxy group, isocyanate group, and hydroxyl group; the n groups A¹ and bonds or groups R² may independently be the same or different; “m” is 1 to 8, “n” is 2 to 9, and m+n is 3 to 10; P¹ represents a polymer skeleton; and the m skeletons P¹ may be the same or different.

The present invention is directed to novel organometallic complexes as catalysts for the reaction of compounds with isocyanate and hydroxyl functional groups to form urethane and/or polyurethane and the process employing such catalysts. More particularly, the present invention is directed to novel complexes of zinc(II) with substituted amidines. These novel catalysts are useful for the production of urethanes and polyurethanes which are important in many industrial applications.

The method of the present invention for producing a urethane-based thermoplastic elastomer composition foam comprises the steps of:

• • adding and mixing 0.1 to 30 parts by weight of carbon dioxide (B) to 100 parts by weight of a urethane-based thermoplastic elastomer composition (A) in a molten state, wherein said urethane-based thermoplastic elastomer composition (A) comprises a urethane-based thermoplastic elastomer (A-1) and other thermoplastic elastomer (A-2) in an (A-1)/(A-2) ratio of 20/80 to 99/1 by weight, to form a molten urethane-based thermoplastic elastomer composition (C) which is in a state of a mixture of the urethane-based thermoplastic elastomer composition (A) and the carbon dioxide (B) (gas dissolving step); and
  • lowering a temperature of said molten urethane-based thermoplastic elastomer composition (C) (cooling step).

The present invention can produce the urethane-based thermoplastic elastomer foam of stable quality over a range from low foamed product to highly foamed product by adding a given quantity of carbon dioxide in the molten urethane-based thermoplastic elastomer quantitatively and stably. It can also produce the foam excellent in flexibility, thermal insulation and surface appearances. It is also excellent in safety, because of use of carbon dioxide in place of the common foaming agent of fluorochlorohydrocarbon or butane, thus causing no air pollution or destruction of the ozone layer.